Table 2.

Characteristics of the HSCT patients receiving MSC

Patient				Hematopoietic stem cell transplantation						Mesenchymal stromal cell transplantation:
UPN:	Sex:	Age:	Diagnosis:	Match:	Cell source:	Conditioing:	Anti-T-lymph:	GvHD prophyl:	aGvHD:	Indication:	Match:	Day:	Passage:	Dose × 10⁶/kg:	Effect of MSC:	Outcome:
995	M	59	AML	Sibling	PBSC	Bu+Cy	X	CsA+MTX	III	aGvHD	Sibling	57	2	1.4	CR	alive, 3 y and 11 m, bronchiolitis, status post-HD
1020	M	38	ALL	Sibling	PBSC	fTBI+Cy		CsA+MTX	II	Engraftm	Sibling	0	2	1.0	n/a	A & W, 4 y and 1 m
1110	F	12	SAA	Sibling	BM	Flu	X	CsA	-	Engraftm	Sibling	0	2	1.1	n/a	A & W, 2 y and 9 m
868	M	27	CML	MUD	BM	Flu+TBI	X	CsA+MMF	II	cGvHD	Haplo	153	1	0.6	NR	died, 1 y and 0 m, PTLD
917	M	61	Renal cancer	MUD	PBSC	Flu+TBI	X	CsA+MTX	IV*	aGvHD	Haplo	242	3	1.0	NR	died, 0 y and 9 m, progression, aspergillosis, adenovirus- and CMV- disease
924	M	9	ALL	MUD	PBSC	fTBI+Cy	X	CsA+MTX	IV	aGvHD	Haplo	73	1	2.0	CR	died, 1 y & 7 m, penumonitis
994	F	34	AML	MUD	PBSC	Bu+Cy	X	CsA+MTX	I	Engraftm	Haplo	0	2	1.4	n/a	A & W, 4 y and 6 m
1033	M	22	ALL	MMUDm	CB	fTBI+Cy	X	CsA+Pred	III	Hem cyst	Haplo	81	1	0.7	PR	died, 0 y and 3 m, MOF
1047	M	9	SAA	MMUDs	BM	fTBI+Cy	X	Tacro+Siro	II	Engraftm	Haplo	0	2	1.0	n/a	A & W, 4 y 2 m
1126	M	1	SCID	MMUDm	CB	Bu+Cy	X	CsA+Pred	I	Engraftm	Haplo	0	3	1.0	n/a	died, 0 y and 8 m, aspergillosis
981	F	21	ALL	MUD	PBSC	fTBI+Cy	X	CsA+MTX	I	Pneumo	MM	474	2	0.7	CR	died, 1 y & 4 m, relapse
1007	M	59	Prostate cancer	MUD	PBSC	Flu+Cy	X	CsA+MTX	III*	aGvHD	MM	251	3	0.7	PR	died, 1 y and 7 m, disseminated VZV
1044	M	60	Myeloma	Sibling	PBSC	Flu+TBI		CsA+MMF	III	aGvHD	MM	77	2	0.9	CR	died, 2 y and 2 m, relapse
1068	F	34	ALL	Sibling	PBSC	fTBI+Cy		CsA+MTX	III	aGvHD	MM	32	2	2.0	PR	died, 0 y and 6 m, penumonia sepsis
1082	F	64	CLL	Sibling	PBSC	Flu+TBI		CsA+MTX	III	aGvHD	MM	49	2+3	1.7	PR	died, 0 y and 4 m, invasive fusarium, aspergillosis
1098	M	13	Thalassemia	Sibling	BM	Bu+Cy		Tacro+Siro	-	Hem cyst	MM	24	2	1.6	CR	A & W, 3 y and 0 m
1115	M	55	CML	MUD	BM	Bu+Cy	X	CsA+MTX	III	aGvHD	MM	103	3	1.1	n/a	died, 0 y and 10 m, MOF
1118	M	54	AML	Sibling	PBSC	Bu+Cy		CsA+MTX	I	Hem cyst	MM	48	3	0.75	CR	alive, 1 y and 10 m, cGvHD in eyes

UPN, unique patient number; M, male; F, female; CML, chronic myeloid leukemia; ALL, acute lymphatic leukemia; AML, acute myeloid leukemia; SAA, severe aplastic anemia; CLL, chronic lymphatic leukemia; SCID, severe combined immunodeficiency disorder; MUD, HLA matched unrelated donor; MMUDm; major HLA mismatched unrelated donor; MMUDs, subtype HLA mismatched unrelated donor; BM, bone marrow; PBSC, peripheral blood stem cells; CB, cord blood; Flu, fludarabine; TBI, total body irradiation; fTBI, fractionated total body irradiation; Cy, cyclophosphamide; Bu, busulphan; Anti-T-lymphocyte; anti-T-lymphocyte prophylaxis; GvHD phophyl, graft-versus-host-disease prophylaxis; CsA, cyclosporine A; MMF, mycophenolate mofetil; MTX, methorexate; Pred, predisolone; Tacro, tacrolimus; Siro, sirolimus; aGvHD, acute graft-versus-host-disease; cGVHD, chronic graft-versus-host-disease; Penumo, penumomediastinum; Engraftm, engraftment; Hem cyst, hemorrhagic cystitis; Haplo, HLA halploidentical; MM, mismatched; NR, no response; CR, complete remission; PR, partial response; n/a, not applicable; y, years; m, months; PTLD, post-transplant lymphoproliferative disorder; CMV, cytomegalovirus; A & W, alive and well; HD, Hodgkin’s disease; VZV; varicella zoster virus infection; MOF, multiorgan failure.